We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 883

Germany - unhealthy showdown
  • Freshfields Bruckhaus Deringer LLP
  • Germany
  • July 5 2013

The German government has signalled its intention to fight corruption in the healthcare sector before its current term of office comes to an end


Germany
  • BARDEHLE PAGENBERG Partnerschaft mbB
  • Germany
  • September 17 2013

On the regulatory side, the Federal Institute for Drugs and Medical Devices is the authority competent to grant a national marketing authorisation for


The Bolar exemption protection of API suppliers
  • Bird & Bird
  • European Union, Germany
  • May 18 2014

The CJEU has recently been asked by the German courts to consider whether the Bolar exemption extends to a third party manufacturer which supplies a


German court re-enforces incentives ban against manufacturer: no touchpads for increased sales
  • Jones Day
  • Germany
  • December 6 2012

Medical device manufacturers whose products more closely resemble consumer goods may be inclined to lose sight of German health care compliance legislation


New draft German law regarding anti-corruption in the healthcare sector
  • Hogan Lovells
  • Germany
  • February 4 2015

We would like to inform you that the German Ministry of Justice recently provided a new draft anticorruption law explicitly referring to the


Update on recent case law restricting advertising of medicinal products
  • Baker & McKenzie
  • Germany
  • February 6 2015

Recent court decisions confirm the rigorous standard ("Strengeprinzip") applied by German courts when analyzing whether or not health claims in


CJEU referral of the Düsseldorf Court of Appeal regarding third party supply for Bolar exemption purposes (now available in English)
  • Taylor Wessing
  • European Union, Germany
  • January 14 2014

Last month the Düsseldorf Court of Appeal has referred questions to the CJEU on whether and under what conditions the supply of patent protected


Acute impact decision on descriptive additions to pharmaceutical brand names
  • Latham & Watkins LLP
  • Germany
  • August 8 2013

The Higher Administrative Court of Northrhine-Westphalia (Oberverwaltungsgericht NRW OVG-NRW) has upheld a decision by the Administrative Court of


Sidley Austin LLP global pricing newsletter - volume three 2014
  • Sidley Austin LLP
  • Brazil, Canada, China, European Union, France, Germany, India, United Kingdom, USA
  • April 15 2014

On October 21, 2013, Brazil’s National Agency of Supplemental Health enacted Normative Resolution 388, which mandated that all private healthcare


FSC decides on patentability of neural progenitor cells II (Brustle)
  • Bird & Bird
  • Germany
  • February 25 2013

Recently, the German Federal Supreme Court decided on a nullity action on the patentability of progenitor cells extracted from human embryonic stem